Navigation Links
Researchers study new drug and indications for heated chemotherapy treatment

WINSTON-SALEM, N.C. Studies have shown that surgery combined with Intraperitoneal Hyperthermic Chemotherapy (IPHC) can improve survival rates for select patients with peritoneal carcinoma (cancer of the lining of the abdominal cavity) that has spread from colorectal or appendix cancer.

Researchers from Wake Forest University School of Medicine will present findings from two studies on the use of IPHC in treating peritoneal cancer that has spread from these two primary cancer sites at the annual meeting of the Society of Surgical Oncology in Chicago, March 13-16.

John H. Stewart, IV, M.D., assistant professor of surgery, section of surgical oncology, reports March 13 on the results of a study evaluating toxicity when combining surgery and IPHC using oxaliplatin as the chemotherapy agent in patients with peritoneal cancer which originated as colorectal or appendix cancer.

A large body of literature suggests that oxaliplatin is superior to other chemotherapy agents in killing colorectal cancer cells, said Stewart. Further, we have previously demonstrated that the cancer-killing effects of oxaliplatin are increased when the agent is heated during perfusion.

The purpose of the phase I study was to establish the maximum tolerated dose of oxaliplatin used in IPHC treating colorectal and appendix cancers that have spread to the peritoneum.

Fifteen patients were enrolled in the study at two dose levels, 200 mg/m and 250 mg/m. At the maximum tolerated dose of 200 mg/m, only two significant toxicities were encountered. More severe toxicities were observed in patients receiving 250 mg/m.

Researchers concluded that IPHC with 200 mg/m of oxaliplatin is well tolerated and is the maximally tolerated dose for a two-hour chemoperfusion.

Based on the data from this phase I study, we propose to conduct a larger trial with oxaliplatin dose to study its efficacy in improving outcomes in patients with peritoneal carcinoma, said Stewart.

On March 14, Perry Shen, M.D. associate professor, section of surgical oncology, will report findings on the use of IPHC in patients with peritoneal cancer and hepatic metastases (HM), or liver cancer that has metastasized from colorectal cancer. The use of IPHC in patients with this presentation is controversial.

This was a retrospective study of 144 patients undergoing surgery to remove as much of the cancer as possible and IPHC between 1991 and 2007, said Shen. There were 17 patients with HM. Clinical and pathological information was obtained from a prospectively collected database and electronic medical record.

Median overall survival for patients with and without HM was 22.7 months and 15.8 months respectively, which was not a significant difference. Two- and four-year survival rates for the HM patients were 34.0 percent and 11.3 percent. Further analysis demonstrated the presence of malignant fluid in the abdominal cavity to be a significant predictor of decreased survival in patients with HM.

We concluded that patients with peritoneal carcinoma and hepatic metastases undergoing cytoreductive surgery and IPHC for colorectal cancer had no significant difference in overall survival compared to those without HM, said Shen. In select patients with peritoneal carcinoma and hepatic metastases, cytoreductive surgery and IPHC may have some benefit. Malignant ascites, an accumulation of fluid in the peritoneal cavity, predicted a poor outcome.


Contact: Jonnie Rohrer
Wake Forest University Baptist Medical Center

Related medicine news :

1. Researchers use light to detect Alzheimers
2. Penn researchers identify first sex chromosome gene involved in meiosis and male infertility
3. Mayo Researchers Say ECG Standards Should Be Revised for Elderly
4. Mayo researchers say ECG standards should be revised for elderly
5. Researchers confirm link between common cold and ear infection
6. Researchers make case for standardized analysis of cardiac imaging
7. Researchers find cause of severe allergic reaction to cancer drug
8. Researchers develop a method to select eggs with the best chance of leading to successful pregnancy
9. USC researchers find benefit for lymphoma patients in combined PET-CT scanning
10. Researchers ID behavioral risk factors for head and neck cancers
11. Red-light cameras increase crashes, researchers find
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... Being a caregiver for someone you love ... Care System, the Caregiver Support Program promotes the health and wellbeing of family ... percent report that their role as a caregiver has created marital strain,” said ...
(Date:11/30/2015)... ... 30, 2015 , ... During the National Family Caregivers Month, ... two webinars on topics of ‘Medical and Palliative Care Decisions,’ and ‘Self-Care for ... . , With a loved one's diagnosis of mesothelioma, the closest family member ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... (NADL), only four states in the U.S. require dental technicians to be certified ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... . The directory is specialized and only includes chiropractic clinics in the US. ... competent and trustworthy alternative health practitioner when back pain sets in. When people ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... driverless vehicle experience this summer, ushering in a new era of publicly accessible ... and electric shuttle, will continue to offer guests an up-close look at the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015 MEDTEC Japan 2016, Asia,s ... industry, is to be held in Tokyo from 20 th  - 22 nd ... --> -->   --> ... the United States . With the aging population and the ... to grow steadily. --> the United States . With ...
(Date:11/30/2015)... Vascular Ltd., together with its subsidiaries (the "Company" or ... LLC and Quattro Vascular Pte. Ltd., collectively the "Group"), ... distribution of advanced therapeutic solutions for the minimally invasive ... a three-judge panel of the United States ... ("Federal Circuit") has unanimously granted the Group and Dr. ...
(Date:11/30/2015)... , Nov. 30, 2015  DURECT Corporation ... Matt Hogan , Chief Financial Officer, ... Conference on Tuesday, December 8 at 2:45 ... held at the Westin Grand Central Hotel ... available for one-on-one meetings at this conference; ...
Breaking Medicine Technology: